Ecolab’s Purolite resin business and Repligen Corp., a life sciences company focused on bioprocessing technology, have commercially launched Purolite’s DurA Cycle, a protein A chromatography resin for large-scale purification processes. This new affinity resin, introduced at the BIO International Convention in San Diego, marks a significant milestone in Purolite’s long-term strategic partnership with Repligen to advance the bioprocessing.
 
DurA Cycle is designed for large-scale commercial manufacturing of monoclonal antibodies, where cost of goods is critical for biologic drug developers. This new resin represents the latest addition to Purolite’s toolbox, following two new resins launched in the last eighteen months to address purification challenges associated with increasingly complex drugs.
 
Srini Paluri, senior vice president and general manager at Purolite, said, “The launch of DurA Cycle chromatography resin underscores Ecolab’s 100-year heritage of innovation and ongoing investment in Purolite, reaffirming our commitment to the bioprocessing industry. This new resin enables biologic developers to increase manufacturing efficiencies, reduce their cost of goods, and accelerate the delivery of innovation to the clinic.”
 
Ralf Kuriyel, vice president of research & development at Repligen, emphasized the significance of the partnership, said, “The bioprocessing industry is seeking partnerships that can effectively address the most complex challenges in biologic manufacturing. Our collaboration with Purolite, an Ecolab Company, advances industry progress by delivering cutting-edge solutions that meet these demands. Together, we are paving the way for the future of bioprocessing.”
 
Purolite’s latest resin follows news of its investment in a new bioprocessing production facility based in Landenberg, PA, which complements its UK-based facility, providing dual continent manufacturing capabilities.